



Current Clinical Trials for SADS Conditions

ARVC

- **Implicit Bioscience**

- The goal of this clinical trial is to test IC14 (atibucimab) in patients with arrhythmogenic cardiomyopathy (ACM) and who have an implantable cardioverter/defibrillator in place.
- <https://clinicaltrials.gov/study/NCT06275893?cond=Arrhythmogenic%20Right%20Ventricular%20Cardiomyopathy&aggFilters=funderType:industry,phase:1&rank=1>
- St. Louis, MO - Not yet recruiting

- **Lexeo**

- This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
- <https://clinicaltrials.gov/study/NCT06109181?cond=Arrhythmogenic%20Right%20Ventricular%20Cardiomyopathy&aggFilters=funderType:industry,phase:1&rank=4>
- No sites listed - Not yet recruiting

- **Rocket**

- This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
- <https://clinicaltrials.gov/study/NCT05885412?cond=Arrhythmogenic%20Right%20Ventricular%20Cardiomyopathy&aggFilters=funderType:industry,phase:1&rank=3>
- La Jolla, CA and Philadelphia, PA - Recruiting

- **Tenaya**

- This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
- <https://clinicaltrials.gov/study/NCT06228924?cond=Arrhythmogenic%20Right%20Ventricular%20Cardiomyopathy&aggFilters=funderType:industry,phase:1&rank=2>
- Rochester, MN and Baltimore, MD - Not yet recruiting

Supporting Families. Saving Lives.

CPVT

- **ARMGO**

- The goal of the proposed project is to determine the safety and tolerability as well as the preliminary efficacy of a novel small molecule drug, S48168 (ARM210), for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1).
- <https://clinicaltrials.gov/study/NCT05122975?cond=Catecholaminergic%20Polymorphic%20Ventricular%20Tachycardia&aggFilters=funderType:industry&rank=1>
- Rochester, MN and Amsterdam - Recruiting

- **Cardurion**

- This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
- <https://clinicaltrials.gov/study/NCT06005428?cond=Catecholaminergic%20Polymorphic%20Ventricular%20Tachycardia&aggFilters=funderType:industry&rank=2>
- Cincinnati, OH - Recruiting

LQTS

- **Thryv**

- Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects. This is a 2-treatment, 2-period crossover study with approximately up to 28 healthy subjects, with screening procedures within 28 days of enrolment.
- Part 2: This is a Phase 2a, single-blind, placebo run-in, multiple-dose safety study to evaluate the safety, tolerability, and PK of LQT-1213 in patients diagnosed with LQT2 or LQT3. Up to 12 participants with LQT2 and up to 12 participants with LQT3 will be recruited.
- <https://clinicaltrials.gov/study/NCT05906732?cond=Long%20QT%20Syndrome&aggFilters=funderType:industry&rank=2>
- West Bend, WI - Recruiting